Aptevo Therapeutics Reports $6.5 Million Q3 Loss and $8.3 Million in Cash
Aptevo Therapeutics reported a Q3 2026 net loss of $6.5M and $8.3M in cash. Clinical progress for mipletamig showed 79% remission in high-risk AML patients. August financing raised $4.5M gross. Phase 1b RAINIER trial nears completion, with regulatory interaction planned for 2027.
How this was made

The 30-second read
Why it matters
The disclosed Q3 loss and cash position raise short‑term financing risk, but the 79% remission rate in TP53‑mutated AML patients provides a compelling data point that may attract investors seeking early‑stage oncology breakthroughs.
Market read
First‑time disclosure of earnings and trial data for a micro‑cap biotech; relevant for traders monitoring biotech earnings and early‑stage trial outcomes.
What to watch
Potential upcoming financing round or partnership could mitigate cash concerns.
Background
Aptevo Therapeutics (NASDAQ:APVO) is a clinical‑stage biotech focused on trispecific antibodies for oncology.
Ticker impact
Aptevo Therapeutics filed an 8‑K reporting Q3 2026 net loss of $6.5 M, cash of $8.3 M and positive Phase 1b data for mipletamig in TP53‑mutated AML.
likely downward pressure as the market prices the loss and cash shortage, tempered by potential upside from the trial results
Micro‑cap biotech stocks react sharply to earnings misses and cash constraints, but positive early‑stage data can limit sell‑offs and attract speculative buying.
Market effects
Highlights ongoing interest in TP53‑mutated AML therapies, may spur peer biotech attention.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche oncology investors.
Counterpoint
Despite cash constraints, the high remission rate could justify a short‑term rally on speculative buying.
Key entities
- companyAptevo Therapeutics
Clinical‑stage biotech developing mipletamig for AML.